AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
- Latest
- Trending
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Babcock & Wilcox secures $13 million contract to provide environmental equipment to a North American petroleum refinery. The deal includes ...
Mining giant Glencore plans to sell its stake in the Koniambo Nickel venture due to mounting losses from falling nickel ...
Foodstuffs North Island is trialing facial recognition technology to combat retail crime in New Zealand. The six-month trial will assess ...
Stock futures dip as S&P 500 hits another record high. Diamondback Energy considers merger, Microsoft surpasses Apple in market cap, ...
Citi raises its price target on Generac Holdings, a leading power generation equipment manufacturer, to $128. However, they maintain a ...
Glencore is actively looking for a buyer for its stake in the Koniambo Nickel joint-venture amid slumping prices. The move ...
Train drivers at BHP Group's Australian iron-ore operations plan to strike over working conditions. Disruptions could impact production and profits ...
Asian stocks traded in a narrow range due to many major markets being closed for Chinese New Year. Australian market ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.